WSJ: Syrian army is about to retake militant-controlled east AleppoWorld December 06, 8:48
OSCE chief says trip to Crimea possible after consultations with Moscow and KievWorld December 06, 8:25
Erdogan signs bill to ratify Turkish Stream projectBusiness & Economy December 06, 8:19
Russia, India to hold joint naval drills on December 14-21Military & Defense December 06, 7:36
YouTube, Facebook, Twitter, Microsoft team up to fight terrorism contentSociety & Culture December 06, 6:51
Russian hospital shelling 'cold-blooded murder' - Defense MinistryWorld December 06, 5:32
Some 100,000 Aleppo residents freed from rule of terrorists — Syria’s UN envoyWorld December 06, 5:04
Over 1,000 Syrian settlements join reconciliation process - Russian defense ministryWorld December 06, 3:27
Italian president asks Renzi to delay resignation until budget passedWorld December 06, 3:24
RESEARCH TRIANGLE PARK, North Carolina, March 21, 2016 /PRNewswire/. Marken reported today the results of Marken's opening event and workshop in Moscow, commemorating the opening of their newest fully owned and operated depot. The theme of the event was: Innovations in Clinical Trial Logistics. The event was well attended by local clients, future clients and industry partners.
Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO
Marken CEO Wes Wheeler and Anastacia Kurianova, head of Marken's local operations and Technical Director, welcomed guests to the event which was followed by a tour of the facility. The speakers focused on the latest trends in the clinical research industry, including: patient centricity, late stage customization, and e-labelling. Presentations were given by Sascha Sonnenberg, Marken's Vice President Global CTD Sales & Operations and Frank Jäger of Faubel, a leading provider of e-labeling technology.
Wes Wheeler's opening remarks underscored Marken's interest in Russia by stating that, "Russia continues to be an important source of patients for global clinical trials. 203 new clinical trials were registered in the third quarter of 2015, a 14% increase in one year. Our research suggests that CROs are interested in Russia because clinical trials can be 60-70% less expensive than in other European countries. In 2015, Marken shipped over 150,000 temperature controlled drug products and biological samples in and out of Russia. With the strong numbers of new clinical trials, and now having an important new location in Moscow, we are well placed to expand our business in the country."
Gerit Offenhauser, Marken's SVP of Clinical Trials Distribution further commented, "Our newest Russian depot offers clients new options to store biological sampling kits, perform late stage customization services, and offer our clients the option to be their importer of record. Our clients tell us that these are key decision-making factors when choosing a supply chain logistics partner. Marken's newest depot offers clients all ranges of temperature-controlled storage from -20 and 2-8 degrees to controlled room temperature, plus the option for liquid nitrogen storage. In addition to the dedicated space for drug product storage, standard services such as pick and pack, drug return and destruction and labeling services are offered within this depot and throughout the Marken network."
The new Moscow facility is managed by the company's global inventory system, Marken Solo™, and as with all Marken-owned depots, offers clients real time access to live data reporting on environmental conditions inside the depot. Solo connects to Marken's Maestro system which books and tracks all shipments into and out of the depot on a real time basis.
Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant depot network and logistic hubs in 43 locations worldwide. Marken's 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the pharma and logistics industry.
CONTACT: Christine Noble, firstname.lastname@example.org, +1 919 474 6890, www.marken.com